620,000 shares per hour for first 1 1/2 hours.
Down another 9 cents.
Looks like J&J may decide NOT to continue work on this drug.
HOPE NOT but that's how I see it!
The telomerase inhibitor imetelstat in patients (pts) with intermediate-2 or high-risk myelofibrosis (MF) previously treated with Janus kinase (JAK) inhibitor: A phase 2, randomized study.
Poster Board: #67a
Ayalew Tefferi, MD - Presenter
Only a POSTER not a ORAL PRESENTATION
150,000 shares per hour for first 3 1/2 hours.
Forget the POSTER. Authors stick names on it to acknowledge cooperation in the research.
Wait for JNJ to talk results NEXT YEAR.
This is a POSTER.
Why can't you people get the insignificance of that fact?
Geron is worthless.
The street knows best.
Just another poster session.